Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Assets: 2018-2025

Historic Current Assets for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to $249.2 million.

  • Arcturus Therapeutics Holdings' Current Assets fell 24.67% to $249.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $249.2 million, marking a year-over-year decrease of 24.67%. This contributed to the annual value of $306.0 million for FY2024, which is 20.85% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Current Assets stood at $249.2 million, which was down 9.22% from $274.5 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Current Assets high stood at $470.0 million for Q1 2021, and its period low was $246.7 million during Q3 2022.
  • Its 3-year average for Current Assets is $341.1 million, with a median of $347.0 million in 2024.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 637.14% in 2021, then slumped by 41.40% in 2022.
  • Arcturus Therapeutics Holdings' Current Assets (Quarterly) stood at $379.0 million in 2021, then increased by 6.43% to $403.3 million in 2022, then dropped by 4.15% to $386.6 million in 2023, then decreased by 20.85% to $306.0 million in 2024, then decreased by 24.67% to $249.2 million in 2025.
  • Its last three reported values are $249.2 million in Q3 2025, $274.5 million for Q2 2025, and $278.8 million during Q1 2025.